Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metralindole is a heterocyclic β-carboline derivative classified as a tetracyclic antidepressant. It was developed and used primarily in Russia as an antidepressant agent. Metralindole acts as a reversible inhibitor of monoamine oxidase A (RIMA), increasing the levels of monoamine neurotransmitters such as serotonin and norepinephrine in the brain. This mechanism is similar to that of moclobemide but with its own distinct chemical structure. The drug appears as an off-white odorless powder with a bitter taste and is soluble in water[6][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metralindole.